Salute e Benessere

Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period…

Key Takeaways from the Friedreich's Ataxia Market Report Key Takeaways from the Friedreich's Ataxia Market Report Discover which therapies are expected to grab the Friedreich's ataxia therapeutics market share @Friedreich's Ataxia Market Report Friedreich's Ataxia Market Dynamics The Friedreich's ataxia market dynamics are expected to change in the coming years.Advances in the understanding of Friedreich's ataxiahave significantly clarified the role of frataxin and the...
PR Newswire
05/06/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 05/31/2025100,325,22989,110,384For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
05/06/2025

Fitness Superstore Appoints Antony Morrison as New Commercial Sales Development…

This strengthening of leadership is to drive B2B Growth in the Commercial Fitness marketplace which coincides with their exclusive partnership with SHUA Fitness. This strengthening of leadership is to drive B2B Growth in the Commercial Fitness marketplace which coincides with their exclusive partnership with SHUA Fitness. Antony joins Fitness Superstore with over 15 years of commercial leadership experience in the fitness industry, including a decade specialising in commercial gym equipment...
PR Newswire
05/06/2025

Roquette Appoints Thierry Fournier as Chief Executive Officer

Roquette Appoints Thierry Fournier as Chief Executive OfficerLille, France, June 5, 2025 -Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, announces the appointment ofThierry Fournieras its newCEO, effectiveJuly 18, 2025.Thierry Fournier is currently the CEO of the Southern Europe, Middle East and Africa Region for Saint-Gobain, a global leader in light and sustainable construction, with over...
Nasdaq GlobeNewswire
05/06/2025

BASTIDE : Disposal of DORGE and DYNA MEDICAL in Belgium

Caissargues, June 5, 2025 Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for homecare and orthopedics, and Dyna-Médical, specialist in the manufacture, fitting and sale of custom-made medical devices including bandages, orthotics…
Actusnews Wire
05/06/2025

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2…

IXCHIQ ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, although more robust with the full doseSix-month data confirm full dose selection for pivotal Phase 3 trialSaint-Herblain (France), June 5, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month...
Nasdaq GlobeNewswire
05/06/2025

As Pilgrims Arrive in Makkah, Saudi Arabia Rolls Out Massive Operation to…

The Ministry of Health reports 111,400 medical services have been delivered in the first days of the pilgrimage. New technologies include drones that deliver medical supplies in just 5 minutes, AI-augmented diagnostics and wearables to monitor vulnerable pilgrims. "I'm incredibly proud of our healthcare workers who are delivering comprehensive care around the clock. Their dedication has already provided 111,400 medical services since Hajj began and this level of support will...
PR Newswire
05/06/2025

Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR |…

Browse in-depth TOC on "Oligonucleotide Synthesis Market" Browse in-depth TOC on "Oligonucleotide Synthesis Market" 568 - Tables77 - Figures455 - Pages By product,the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2024, the ASOs or antisense oligonucleotide-based drugs segment accounted for the largest share of the market. ASOs are short,...
PR Newswire
05/06/2025

LILYSILK Shares 2024 Impact Report on World Environment Day, Underscoring Its…

The company also continues to improve its packaging practices. In 2024, 99% of LILYSILK's outer packaging was degradable, with a goal of reaching 100% by 2026. Many materials now carry FSC® certification. The company also continues to improve its packaging practices. In 2024, 99% of LILYSILK's outer packaging was degradable, with a goal of reaching 100% by 2026. Many materials now carryFSC®certification. LILYSILK's dedication extends to supplier partnerships. The company maintains a...
PR Newswire
05/06/2025

Nanox Receives MDR CE Mark for HealthOST, an Advanced AI-Powered Software for…

HealthOST identifies vertebral height loss and bone mineral density, which are key indicators of musculoskeletal diseaseOsteoporosis is a common progressive bone disease among adults over 50 years of age that causes bones to weaken, leading to fracturesThe software provides automated quantification of vertebral parameters from routine CT scans, delivering consistent and objective data to support physician evaluation, before life-altering fractures occurPETACH TIKVA, Israel, June05,...
Nasdaq GlobeNewswire
05/06/2025

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular…

Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC…
PR Newswire
05/06/2025

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and…

As a member of Medicines for Europe, Polpharma Group joins industry leaders in calling on EU Prime Ministers to adopt a 5-Point Pharmaceutical Action Plan to protect patients, boost manufacturing, and ensure fair competition Polpharma Group, a leading European pharmaceutical manufacturer, has joined fellow members of Medicines for Europe in signing an open letter addressed to the Prime Ministers and Ministers of Health of all 27 EU Member States. The letter calls for urgent political action...
Nasdaq GlobeNewswire
05/06/2025

Avicenna.AI Secures CE Mark for Two Spine-Focused Medical Imaging AI Tools

The CE mark signifies that both products meet the stringent health and safety standards required by the European Union, enabling them to be deployed across the European Economic Area without additional regulatory barriers. The CE mark signifies that both products meet the stringent health and safety standards required by the European Union, enabling them to be deployed across the European Economic Area without additional regulatory barriers. VCFs, often caused by bone deterioration due to...
PR Newswire
05/06/2025

Philips Foundation 2024 Annual Report: expanding access to quality healthcare…

In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South AmericaCelebrating a decade of impact with strong progress towards the Foundation's 2030 goal to improve access to healthcare for 100 million people in underserved communities a yearThe combined impact of longstanding strategic collaborations and new innovative partnerships with healthcare ventures affirm the...
Nasdaq GlobeNewswire
05/06/2025

Global Nutraceutical Products Market Estimated to Reach USD 912.25 Billion by…

Additionally, there's a growing focus on medical nutrition, especially with dietary supplements being used to address issues like heart disease and malnutrition. The aging population, rising healthcare costs, and changing lifestyles, combined with investments from established companies in new product development, are expected to boost the market further. Overall, the nutraceuticals market is evolving to provide better solutions for people's health needs. Additionally, there's a growing focus…
PR Newswire
05/06/2025

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025.Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11 thyear, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company's growth and results. In 2024 alone, more than 32,000 Sanofi employees - 40% of the total workforce, chose to invest in the company through the...
Nasdaq GlobeNewswire
05/06/2025

Oculis Publishes Results of 2025 Annual General Meeting

/ XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company's shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory...
Nasdaq GlobeNewswire
05/06/2025

Philips announces exchange ratio for 2024 dividend

Amsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of...
Nasdaq GlobeNewswire
05/06/2025

Sectra's year-end report 2024/2025: Reporting solid growth in a time of change

Fourth quarter: February–April 2025 Fourth quarter: February–April 2025 Comments from Torbjörn Kronander, President and CEO of Sectra AB– "Our long-term efforts to create value for healthcare and society, and ultimately our shareholders, are continuing to deliver good results in 2024/2025. We took major steps forward in our core areas—medical IT and cybersecurity—where we deliver solutions that improve people's quality of life and safety all over the world.– The past fiscal year can...
PR Newswire
05/06/2025

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar…

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy's”), today announced that the companies have entered into a collaboration and license agreement to co-develop,...
Nasdaq GlobeNewswire
05/06/2025

Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany

PSMA-PET imaging represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods such as bone scans and CT[4] scans as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines recognize its superior accuracy in staging primary disease and assessing BCR[5]. Illuccix® PSMA-PET will help address an important clinical need by supporting timely and effective diagnosis, as well as identifying patients who may…
PR Newswire
05/06/2025

EssilorLuxottica signs an agreement to acquire A-Look, Seen and OWL retail…

EssilorLuxottica signs an agreement to acquire A-Look, Seen and OWL retail stores in MalaysiaWith this transaction, the Group aims at further elevating the standards of vision care in the countryParis, France (5 June 2025)– EssilorLuxottica announces today it has signed an agreement for the acquisition of one of the largest optical companies in Malaysia operating over 90 stores under the A-Look, Seen and OWL banners.A-Look was founded in 2003 by Dato Terry Ngeow, with the...
Nasdaq GlobeNewswire
05/06/2025

[Valneva SE] Declaration of shares and voting rights - May 2025

VALNEVADeclaration of shares and voting rightsMay 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: June 5, 2025 Number ofsharescomposing theshare capital of ValnevaTotal numberof voting rights including suspended voting rights*Description of...
Nasdaq GlobeNewswire
05/06/2025

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China…

Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year...
Nasdaq GlobeNewswire
05/06/2025
Altri  Comunicati